These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21035736)

  • 1. hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.
    Mercier RW; Pei Y; Pandarinathan L; Janero DR; Zhang J; Makriyannis A
    Chem Biol; 2010 Oct; 17(10):1132-42. PubMed ID: 21035736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis.
    Mallipeddi S; Kreimer S; Zvonok N; Vemuri K; Karger BL; Ivanov AR; Makriyannis A
    J Proteome Res; 2017 Jul; 16(7):2419-2428. PubMed ID: 28374590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.
    Zhou H; Peng Y; Halikhedkar A; Fan P; Janero DR; Thakur GA; Mercier RW; Sun X; Ma X; Makriyannis A
    ACS Chem Neurosci; 2017 Jun; 8(6):1338-1347. PubMed ID: 28220706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.
    Alqarni M; Myint KZ; Tong Q; Yang P; Bartlow P; Wang L; Feng R; Xie XQ
    Biochem Biophys Res Commun; 2014 Sep; 452(3):334-9. PubMed ID: 25148941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.
    Pei Y; Mercier RW; Anday JK; Thakur GA; Zvonok AM; Hurst D; Reggio PH; Janero DR; Makriyannis A
    Chem Biol; 2008 Nov; 15(11):1207-19. PubMed ID: 19022181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
    Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
    Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-selective labeling and electron paramagnetic resonance studies of human cannabinoid receptor CB
    Yeliseev AA; Zoretich K; Hooper L; Teague W; Zoubak L; Hines KG; Gawrisch K
    Biochim Biophys Acta Biomembr; 2021 Aug; 1863(8):183621. PubMed ID: 33865808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
    Janero DR; Korde A; Makriyannis A
    Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level expression of the human CB2 cannabinoid receptor using a baculovirus system.
    Nowell KW; Pettit DA; Cabral WA; Zimmerman HW; Abood ME; Cabral GA
    Biochem Pharmacol; 1998 Jun; 55(11):1893-905. PubMed ID: 9714308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
    Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
    Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines.
    Oyagawa CRM; de la Harpe SM; Saroz Y; Glass M; Vernall AJ; Grimsey NL
    Front Pharmacol; 2018; 9():1202. PubMed ID: 30524271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
    Deiana V; Gómez-Cañas M; Pazos MR; Fernández-Ruiz J; Asproni B; Cichero E; Fossa P; Muñoz E; Deligia F; Murineddu G; García-Arencibia M; Pinna GA
    Eur J Med Chem; 2016 Apr; 112():66-80. PubMed ID: 26890113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of [
    Attili B; Celen S; Ahamed M; Koole M; Haute CVD; Vanduffel W; Bormans G
    Br J Pharmacol; 2019 May; 176(10):1481-1491. PubMed ID: 30588600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.
    Szymanski DW; Papanastasiou M; Melchior K; Zvonok N; Mercier RW; Janero DR; Thakur GA; Cha S; Wu B; Karger B; Makriyannis A
    J Proteome Res; 2011 Oct; 10(10):4789-98. PubMed ID: 21861534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.
    Zhang Y; Gilliam A; Maitra R; Damaj MI; Tajuba JM; Seltzman HH; Thomas BF
    J Med Chem; 2010 Oct; 53(19):7048-60. PubMed ID: 20845959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliphatic Azides as Selective Cysteine Labeling Reagents for Integral Membrane Proteins.
    Szymanski D; Papanastasiou M; Pandarinathan L; Zvonok N; Janero DR; Pavlopoulos S; Vouros P; Makriyannis A
    J Med Chem; 2018 Dec; 61(24):11199-11208. PubMed ID: 30444608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers.
    Bingham B; Jones PG; Uveges AJ; Kotnis S; Lu P; Smith VA; Sun SC; Resnick L; Chlenov M; He Y; Strassle BW; Cummons TA; Piesla MJ; Harrison JE; Whiteside GT; Kennedy JD
    Br J Pharmacol; 2007 Aug; 151(7):1061-70. PubMed ID: 17549048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.
    Shen CP; Xiao JC; Armstrong H; Hagmann W; Fong TM
    Eur J Pharmacol; 2006 Feb; 531(1-3):41-6. PubMed ID: 16438957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
    McAllister SD; Rizvi G; Anavi-Goffer S; Hurst DP; Barnett-Norris J; Lynch DL; Reggio PH; Abood ME
    J Med Chem; 2003 Nov; 46(24):5139-52. PubMed ID: 14613317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template.
    Zhang R; Hurst DP; Barnett-Norris J; Reggio PH; Song ZH
    Mol Pharmacol; 2005 Jul; 68(1):69-83. PubMed ID: 15840841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.